Dr. Pol Vandenbroucke describes the individual and collective risks associated with rising antibiotic resistance.
Even before the COVID-19 pandemic, it was difficult to articulate the great importance of careful prescribing to patients who request antibiotic treatment. Common misnomers like "strong antibiotic" point to widespread confusion on how antibiotics function.
Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, describes the individual and collective risks associated with antimicrobial resistance from a patient perspective.
Dr. Vandenbroucke then proceeds to compare the ramifications with the impact of COVID-19 on travel and other social activity.
